Elixirgen Therapeutics, Inc.

This early-stage study is testing the safety of an experimental cell therapy called EXG34217 in up to 12 patients with a rare genetic disorder that causes bone marrow failure. The therapy involves collecting a patient's own blood cells, modifying them in a lab to potentially leng…